NOW APPROVED: A NEW CD38-DIRECTED THERAPY

For the treatment of patients with relapsed refractory multiple myeloma

SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.